Flavia Borellini, Ph.D.
Life Cycle Leader, Zelboraf™
Global Product Strategy, Oncology
A member of the Roche Group
Flavia Borellini is currently Life Cycle Leader for Zelboraf at Genentech/Roche.
Since 2009, Flavia has been globally responsible for the development, life cycle management and commercialization of vemurafenib (Zelboraf). Zelboraf was approved in August 2011 by the US FDA for the treatment of patients with BRAF V600E mutated unresectable or metastatic melanoma, together with its companion diagnostic, the cobas 4800 BRAF mutation test, which identifies patients appropriate for treatment with Zelboraf. From 2006 to 2009, Flavia lead the lifecycle development of Tarceva® and Herceptin® in the US.
Prior to joining Genentech in 2006, Flavia held various positions at BioReliance, a major contract research and testing organization, and Cell Genesys, including Vice President of Product Development.
Flavia Borellini holds a PhD in Pharmaceutical Chemistry and Board Certification in Pharmacy from the University of Modena, Italy. She completed her postdoctoral training at the NIDDK and NCI, and was subsequently a research Assistant Professor at Georgetown University.